Smolevichi region executive committee - Belarus’ COVID-19 vaccine to be available for general public in H1 2023

SMOLEVICHI
REGION
EXECUTIVE
COMMITTEE

ADDRESS:

222201, Minsk region,
Smolevichi, st. Sovetskaya, 125 (working hours)
Reception phone: +375 (1776) 4-42-91 "hot line"
Fax: +375 (1776) 2-76-33
Telephone "hot line" of the district executive committee: +375 (1776) 4-42-91 "hot line"

The "hot line" of the Municipal Unitary Enterprise "Smolevichskoe Housing and Public Utilities" is open from 8.00 to 13.00 and 14.00 to 17.00 Monday-Friday by phone +375 (1776) 2-73-68

Single number of reference service "one window" - 142

E-MAIL: isp@smolevichi.gov.by (for business correspondence), the section "Electronic Appeals" for appeals from citizens and legal entities.

ADDRESS:

The "hot line" of the Municipal Unitary Enterprise "Smolevichskoe Housing and Public Utilities" is open from 8.00 to 13.00 and 14.00 to 17.00 Monday-Friday by phone +375 (1776) 2-73-68

Single number of reference service "one window" - 142

E-MAIL: isp@smolevichi.gov.by (for business correspondence), the section "Electronic Appeals" for appeals from citizens and legal entities.

13-08-2021, 10:22

Belarus’ COVID-19 vaccine to be available for general public in H1 2023

Written by user1

Belarus’ own coronavirus vaccine will be available for the general public in H1 2023, Belarusian Healthcare Minister Dmitry Pinevich told reporters on 12 August, BelTA has learned.

“We believe that the vaccine will be available for use in the first half of 2023. When we discuss our strategies, we try to understand whether our research outputs will still be relevant at the end of 2022. Although time is not on our side,the fast pace we are moving at will no way affect quality or safety,” Dmitry Pinevich said.

A reminder, on 12 August Belarusian President Aleksandr Lukashenko inspected the BelVitunipharm company where he was briefed on the progress to create Belarus’ own coronavirus vaccine.

Dmitry Pinevich recalled that this project consists of three stages: laboratory testing, pilot production and mass production. It was decided to locate the pilot production at BelVitunipharm (a separate building will be built here for this purpose) and Belmedpreparaty. “This decision was approved after a serious scrutiny. The mechanism for launching a joint venture will have a direct impact on economic performance. We do not need to set up a separate enterprise now, we will utilize the tried-and-tested premises that meet the highest standards,” the minister added.

Source: БелТА

Read 446 times

Rate this item

(0 votes)

Published in Republik

More in this category: « Belarus president to decide on status of Belarusian People's Congress Great potential for ecological tourism in Belarus »

© Smolevichi District Executive Committee, 2008-2023
SITE DEVELOPMENT - UE «MINSKAYA VOLNA» | INFORMATION SUPPORT UE Information agency «MINSKAYA PRAVDA»

object.onload = function(){myScript}